Tevogen Bio Holdings Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on March 15, 2024, by Tevogen Bio Holdings Inc. (TVGN), a Delaware corporation and emerging growth company. The filing details the formal creation and issuance of two new series of preferred stock following agreements entered into on February 14, 2024.
Key Financial Metrics and Capital Structure
The filing does not provide standard operating financial metrics such as revenue, net income, operating cash flow, or liquidity ratios. The primary financial activity reported is the issuance of preferred stock:
- Series A Preferred Stock: $8 million aggregate purchase price from Dr. Manmohan Patel. Original Issue Price is $4,000 per share.
- Series B Preferred Stock: Issued to the Sponsor in consideration for assuming liabilities totaling approximately $3.6 million (reduced from an initial $4.2 million). Issue Price is $1,000 per share.
Material Changes and Terms
The Company filed Certificates of Designation with the Delaware Secretary of State on March 15, 2024, establishing the following terms:
Series A Preferred Stock
- Ranking: Senior to Common Stock and Series B Preferred Stock regarding dividends and liquidation.
- Dividends: Cumulative, accruing daily at a fixed rate of 5% per annum, automatically increasing by 2% annually. Participates on an as-converted basis in Common Stock dividends.
- Redemption: Callable by the Company at $4,000 plus accrued dividends if the 20-day VWAP of Common Stock exceeds $5.00 and a resale registration statement is effective.
- Conversion: Convertible to Common Stock at the holder's option (subject to adjustments).
- Voting: No voting rights except as required by law.
Series B Preferred Stock
- Ranking: Senior to Common Stock but junior to Series A Preferred Stock.
- Dividends: Quarterly, starting 35 days after issuance at 3.25% per quarter, increasing by 0.25% monthly (capped at 7.5% per quarter). Dividends are paid directly to creditors of the assumed liabilities.
- Redemption: Callable pro rata at the Issue Price.
- Conversion: Not convertible to Common Stock or Series A Preferred Stock.
- Liquidation Preference: Equal to the aggregate amount of liabilities assumed by the Sponsor ($3.6 million).
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the structural terms of the new securities. The issuance of Series B Preferred Stock is contingent on the assumption of specific liabilities by the Sponsor, which are paid via dividend distributions to creditors.
Investor Verification Checklist
- Verify the current volume-weighted average price (VWAP) of Common Stock to assess the likelihood of the Series A redemption trigger ($5.00 threshold).
- Confirm the status of the resale registration statement required for Series A redemption.
- Review the specific liabilities listed in Schedule I of the Assignment and Assumption Agreement to understand the obligations covered by Series B dividends.
- Monitor the Company's cash position to ensure it can meet the escalating dividend obligations on both Series A and Series B Preferred Stock.